Acquire Aktie
ISIN: US0049011044
10.10.2025 19:06:05
|
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.Year to date, Protagonist Therapeutics' stock has gained around 132%, as per data from Benzinga Pro.Partnership May Evolve Into Full OwnershipJohnson & Johnson and Protagonist already share a collaboration to develop an oral therapy targeting plaque psoriasis and ulcerative colitis.Also Read: Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis TrialsUnder their current agreement, Johnson & Johnson holds exclusive rights ...Full story available on Benzinga.comWeiter zum vollständigen Artikel bei Benzinga

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Protagonist Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Acquire Ltd.mehr Analysen
Aktien in diesem Artikel
Protagonist Therapeutics Inc | 87,00 | 29,77% |
|